Celgene reports preliminary earnings, adds JAK inhibitor with Impact deal

Celgene Corp. (NASDAQ:CELG) reported preliminary 2017 results and 2018 guidance generally in line with expectations and said it will acquire Impact Biomedicines Inc. (San Diego, Calif.), gaining a late-stage hematology candidate in the process. The financial figures were presented at the JPMorgan Healthcare Conference in San Francisco.

The company reported 4Q17 sales of psoriasis drug Otezla

Read the full 550 word article

User Sign In